Back to News
I-Mab, operating as NovaBridge Biosciences, announced updated results from its ongoing Phase 1b study of givastomig combined with nivolumab and chemotherapy in first-line metastatic HER2-negative gastroesophageal adenocarcinoma. The provided article text is truncated before any efficacy or safety results are stated, so no outcome or magnitude can be assessed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- Cramer: I asked some tech insiders what to buy. They surprisingly said this drug stock
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
- Moderna CEO Sees Cancer Vaccines Working Beyond Melanoma
- Bottoms Says Georgia Needs Pause on New Data Centers
- Genmab shares jump 13% on colorectal cancer drug trial results